Tech Company Financing Transactions
Comphya Funding Round
Comphya, based in Lausanne, secured $6.3 million in investment from private investors.
Transaction Overview
Company Name
Announced On
7/8/2025
Transaction Type
Debt
Venture Equity
Venture Equity
Amount
$6,300,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to: Launch and execute a U.S. pilot study, with the first site activated at Johns Hopkins following FDA Investigational Device Exemption (IDE) approval announced in January 2025. Prepare for a pivotal U.S. clinical trial planned for 2026, including regulatory and operational groundwork. Expand its ongoing clinical trial in Australia, where early data has shown strong safety and efficacy signals by recruiting additional patients.
Company Information
Company Status
Private & Independent
Industry
Medical Devices & Instruments
Mailing Address
EFPL Innovation Park Bâtiment C
Lausanne, 1015
CH
Lausanne, 1015
CH
Phone
Undisclosed
Website
Email Address
Overview
Our focus is to bring a better and comfortable therapy for erectile dysfunction to patients non-amendable to oral drugs. Comphya is a Swiss medical device company, spin-off from the École Polytechnique Fédérale de Lausanne, specialized in the treatment of erectile dysfunction to patients non-responsive to oral therapy. With an innovation based on neuroprosthetics principle, our mission is to offer a unique and superior treatment.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 7/8/2025: Parspec venture capital transaction
Next: 7/8/2025: Hololight venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. VC investment data records reported here are derived from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs